[HTML][HTML] Immunotherapy in anal cancer

N Dhawan, MZ Afzal, M Amin - Current Oncology, 2023 - mdpi.com
The incidence and mortality of squamous cell carcinoma of the anus has been gradually
increasing globally over the last few decades. The evolution of different modalities, including …

[HTML][HTML] Immune microenvironment and immunotherapeutic management in virus-associated digestive system tumors

P Sarantis, EM Trifylli, E Koustas… - International Journal of …, 2022 - mdpi.com
The development of cancer is a multifactorial phenomenon, while it constitutes a major
global health problem. Viruses are an important factor that is involved in tumorigenesis and …

[HTML][HTML] Development and validation of a cancer-associated fibroblast-derived lncRNA signature for predicting clinical outcomes in colorectal cancer

H Pan, J Pan, J Wu - Frontiers in Immunology, 2022 - frontiersin.org
Cancer-associated fibroblasts (CAFs) are actively involved in cancer progression through
generating extracellular matrix and orchestrating the crosstalk within the tumor …

Genetically light-enhanced immunotherapy mediated by a fluorinated reduction-sensitive delivery system

M Su, J Wang, N Zhao, B Yu, Y Wang, FJ Xu - Biomaterials, 2024 - Elsevier
The lack of safe and efficient therapeutic agent delivery platforms restricts combined
therapy's effect, and combined cancer therapy's multi-component delivery effect needs …

[HTML][HTML] Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders

BM Huffman, H Singh, LR Ali, N Horick… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Original research: Biomarkers of pembrolizumab efficacy in advanced anal squamous cell
carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders - PMC Back …

[HTML][HTML] PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV

L Lovane, S Tulsidás, C Carrilho, C Karlsson - Scientific Reports, 2024 - nature.com
Abstract Programmed death-ligand 1 (PD-L1) is overexpressed in squamous cervical cancer
(SCC) and can be used for targeted immunotherapy. The highest mortality rates of SCC are …

[HTML][HTML] The interplay between anti-angiogenics and immunotherapy in colorectal cancer

BA Maiorano, A Parisi, E Maiello, D Ciardiello - Life, 2022 - mdpi.com
Simple Summary Colorectal cancer is a frequent and lethal neoplasm. The tumor often
creates new vessels to grow and spread—a process called 'angiogenesis'. Therefore, drugs …

[HTML][HTML] Experimental prognostic model integrating N6-methyladenosine-related programmed cell death genes in colorectal cancer

Q Wu, X Fu, X He, J Liu, Y Li, C Ou - Iscience, 2024 - cell.com
Colorectal cancer (CRC) intricacies, involving dysregulated cellular processes and
programmed cell death (PCD), are explored in the context of N6-methyladenosine (m6A) …

[HTML][HTML] Analysis of definitive chemo-radiation outcomes in anal cancer: insights from a tertiary cancer center in the MENA Region

T Alawabdeh, R Abuhijlih, I Mohamed… - Frontiers in …, 2024 - frontiersin.org
Background Outcomes of chemo-radiation (CRT) for anal cancer in Middle East and North
Africa (MENA) are scarce. We aim to report treatment outcomes for anal cancer treated at …

[HTML][HTML] The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy

AMY Chan, G Roldan Urgoiti, W Jiang, S Lee… - Frontiers in …, 2022 - frontiersin.org
Background Programmed death-ligand 1 (PD-L1) expression has been shown to be
prognostic in many cancer types and used in consideration of checkpoint inhibitor …